Clinical and economic impact of COVID-19 on people with obesity in a Spanish cohort during the first pandemic peak.

COVID-19 diabetes mellitus economic burden intensive care unit (ICU) invasive mechanical ventilation (IMV) obesity obesity comorbidities

Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2023
Historique:
received: 17 01 2023
accepted: 09 05 2023
medline: 23 6 2023
pubmed: 21 6 2023
entrez: 21 6 2023
Statut: epublish

Résumé

COVID-19 and obesity relationship has been extensively studied since the COVID-19 outbreak, proving obesity is a risk factor. This study aims to broaden the available information about this association and to evaluate the economic impact of obesity and the COVID-19 disease combination. This retrospective study analyzed a sample of 3,402 patients admitted to a Spanish hospital with available body mass index (BMI) data. The prevalence of obesity was 33.4%. Patients with obesity showed a higher risk of hospitalization (OR 95% ConfidenceInterval [CI]=1.46; [1.24-1.73]; In conclusion, our results suggest a strong association between obesity and adverse COVID-19 outcomes and higher expenditures in patients with both conditions.

Identifiants

pubmed: 37342262
doi: 10.3389/fendo.2023.1146517
pmc: PMC10278591
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1146517

Informations de copyright

Copyright © 2023 M, MA, B, ME, V, F, P, C, A, C and M.

Déclaration de conflit d'intérêts

R-HM reports professional fees from Novo Nordisk, outside the submitted work. MV and PF are employees of Novo Nordisk. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Life Sci. 2021 Nov 1;284:119201
pubmed: 33607159
Obes Facts. 2013;6(1):1-8
pubmed: 23428930
Nutr Metab Cardiovasc Dis. 2021 Mar 10;31(3):769-773
pubmed: 33549434
J Med Virol. 2021 May;93(5):2662-2674
pubmed: 33200825
Endocrinol Diabetes Nutr (Engl Ed). 2021 Feb;68(2):123-129
pubmed: 33162383
Health Econ Rev. 2021 Nov 3;11(1):43
pubmed: 34734323
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Influenza Other Respir Viruses. 2019 Jan;13(1):3-9
pubmed: 30515985
Obes Surg. 2017 Aug;27(8):2058-2066
pubmed: 28261758
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):303-310
pubmed: 32298981
Circulation. 2021 Jan 12;143(2):135-144
pubmed: 33200947
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
MMWR Morb Mortal Wkly Rep. 2021 Mar 12;70(10):355-361
pubmed: 33705371
Rev Esp Cardiol (Engl Ed). 2016 Jun;69(6):579-87
pubmed: 27133458
Ann Acad Med Singap. 2020 Dec;49(12):996-1008
pubmed: 33463658
Obesity (Silver Spring). 2021 Jan;29(1):29-37
pubmed: 32885905
J Healthc Qual Res. 2022 Sep-Oct;37(5):275-282
pubmed: 35331667
J Laparoendosc Adv Surg Tech A. 2018 Aug;28(8):919-924
pubmed: 30010474
J Clin Endocrinol Metab. 2021 Nov 19;106(12):e5030-e5042
pubmed: 34297116
Arch Intern Med. 2008 Aug 11;168(15):1617-24
pubmed: 18695075
J Clin Hypertens (Greenwich). 2013 Jan;15(1):14-33
pubmed: 23282121
Emergencias. 2020 Ago;32(4):233-241
pubmed: 32692000
J Clin Endocrinol Metab. 2005 Jul;90(7):4145-50
pubmed: 15855252
Obes Rev. 2012 Apr;13(4):388-92
pubmed: 22151906
Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E736-E741
pubmed: 32228322
Sci Rep. 2021 Apr 20;11(1):8562
pubmed: 33879826
Infect Dis Poverty. 2020 Jun 29;9(1):80
pubmed: 32600411
Obes Rev. 2020 Oct;21(10):e13095
pubmed: 32686331
Circ Res. 2016 May 27;118(11):1752-70
pubmed: 27230640
Curr Opin Pharmacol. 2016 Aug;29:77-89
pubmed: 27429211
Metabolism. 2021 Apr;117:154373
pubmed: 32949592
Lancet Diabetes Endocrinol. 2021 Jun;9(6):350-359
pubmed: 33932335
PLoS One. 2020 Dec 15;15(12):e0243600
pubmed: 33320875
Obes Rev. 2020 Nov;21(11):e13128
pubmed: 32845580
Int J Infect Dis. 2020 Oct;99:47-56
pubmed: 32721533
Ann Intern Med. 2020 Nov 17;173(10):773-781
pubmed: 32783686
Epidemiol Infect. 2020 Dec 22;149:e11
pubmed: 33349290
Clin Obes. 2021 Apr;11(2):e12442
pubmed: 33554456
Diabetes Metab. 2021 Mar;47(2):101178
pubmed: 32738402
Int J Antimicrob Agents. 2021 Feb;57(2):106249
pubmed: 33259918
Obes Res Clin Pract. 2021 May-Jun;15(3):275-280
pubmed: 33741308
PLoS One. 2010 Mar 15;5(3):e9694
pubmed: 20300571
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1149-1151
pubmed: 32668401

Auteurs

Torrego-Ellacuría M (TE)

Innovation Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Department of Endocrinology and Nutrition, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.

Rubio-Herrera Ma (RH)

Department of Endocrinology and Nutrition, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Department of Medicine, Faculty of Medicine, Universidad Complutense de Madrid, Madrid, Spain.

González López-Valcárcel B (GL)

Department of Quantitative Methods for Economics and Management, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.

Fuentes-Ferrer Me (FF)

Department of Preventive Medicine, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.

Martín V (M)

Department of Market Access and Public Affairs, Novo Nordisk Pharma, Sociedad Anónima (SA.), Madrid, Spain.

Poyato F (P)

Department of Clinical, Medical and Regulatory, Novo Nordisk Pharma, Sociedad Anònima (SA.), Madrid, Spain.

Barber-Pérez P (BP)

Department of Quantitative Methods for Economics and Management, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.

Santucci C (S)

Department of Quantitative Methods for Economics and Management, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy.

Nuñez A (N)

Department of Critical Care, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.

González-Pérez C (GP)

Innovation Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Department of Hospital Pharmacy, Hospital Clínico San Carlos, Instituto de Investigaciòn Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.

Luaces M (L)

Innovation Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH